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Improved Survival After Heart Failure: A Community-Based
Perspective
Samuel W. Joffe, MD; Kristy Webster, MD; David D. McManus, MD, ScM; Michael S. Kiernan, MD; Darleen Lessard, MS;
Jorge Yarzebski, MD, MPH; Chad Darling, MD; Joel M. Gore, MD; Robert J. Goldberg, PhD
Background-—Heart failure is a highly prevalent, morbid, and costly disease with a poor long-term prognosis. Evidence-based
therapies utilized over the past 2 decades hold the promise of improved outcomes, yet few contemporary studies have examined
survival trends in patients with acute heart failure. The primary objective of this population-based study was to describe trends in
short- and long-term survival in patients hospitalized with acute decompensated heart failure (ADHF). A secondary objective was to
examine patient characteristics associated with decreased long-term survival.
Methods and Results-—We reviewed the medical records of 9748 patients hospitalized with ADHF at all 11 medical centers in
central Massachusetts during 1995, 2000, 2002, and 2004. Patients hospitalized with ADHF were more likely to be elderly and to
have been diagnosed with multiple comorbidities in 2004 compared with 1995. Over this period, survival was signiﬁcantly
improved in-hospital, and at 1, 2, and 5 years postdischarge. Five-year survival rates increased from 20% in 1995 to 29% in 2004.
Although survival improved substantially over time, older patients and patients with chronic kidney disease, chronic obstructive
pulmonary disease, anemia, low body mass index, and low blood pressures had consistently lower postdischarge survival rates
than patients without these comorbidities.
Conclusion-—Between 1995 and 2004, patients hospitalized with ADHF have become older and increasingly comorbid. Although
there has been a signiﬁcant improvement in survival among these patients, their long-term prognosis remains poor, as fewer than 1
in 3 patients hospitalized with ADHF in 2004 survived more than 5 years. ( J Am Heart Assoc. 2013;2:e000053 doi: 10.1161/
JAHA.113.000053)
Key Words: acute heart failure • population surveillance • survival • time trends
H eart failure (HF) is a highly prevalent, morbid, and costlydisease, affecting more than 6.6 million Americans and
causing more than 275 000 deaths annually.1 Prior to the
mid-1990s, fewer than 1 in every 5 patients hospitalized with
acute decompensated heart failure (ADHF) survived more
than 5 years.1–3 Over the past 2 decades, however, there
have been numerous advances in the medical and nonphar-
macologic treatment of patients with chronic HF. The use of
these evidence-based therapies has increased rapidly follow-
ing the publication of the American College of Cardiology
Foundation/American Heart Association (ACC/AHA) Clinical
Practice Guidelines for Congestive Heart Failure in 1995.4
Despite encouraging improvements in the management
of patients with HF, there are limited published data, espe-
cially from the more generalizable perspective of a community-
wide investigation, describing changing trends in the in-hospital
and long-term survival of patients hospitalized with ADHF.
The primary objective of this population-based observa-
tional study was to describe trends in short- and long-term
survival in patients hospitalized with ADHF in 4 study years
between 1995 and 2004 in a large central New England
community. A secondary study objective was to examine
factors associated with decreased survival after hospital
discharge for ADHF.
Methods
Data from the Worcester Heart Failure Study were utilized for
this investigation. The Worcester Heart Failure Study is a
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population-based study of residents of the Worcester, MA,
metropolitan area (2000 census=478 000) hospitalized with
ADHF at all 11 central Massachusetts medical centers.5–7
These medical centers include 2 large, tertiary care academic
medical centers and 9 small to midsize community hospitals.
This study was approved by the Institutional Review Board at
the University of Massachusetts Medical School.
The study sample consisted of greater Worcester adults
hospitalized for possible ADHF during the 4 study years of
1995, 2000, 2002, and 2004. These study years were
selected to coincide with population census estimates and
based on the availability of federal grant support. Trained
physicians and nurses performed a standardized review of the
medical records of greater Worcester residents hospitalized at
all 11 medical centers in central Massachusetts with primary
or secondary International Classiﬁcation of Disease (ICD)-9
codes consistent with the presence of possible HF.5–7 A
discharge diagnosis of HF (ICD-9 code 428) was the principal
diagnostic category reviewed. In addition, the medical records
of patients with discharge diagnoses of hypertension, renal
disease, acute cor pulmonale, cardiomyopathy, pulmonary
congestion, acute lung edema, and respiratory abnormalities
were reviewed to identify patients who may also have had new
onset HF.5–7
The diagnosis of ADHF in greater Worcester residents
presenting to all area hospitals with signs and symptoms of
HF was conﬁrmed based on the Framingham criteria, requiring
the presence of 2 major criteria (e.g., rales, distended neck
veins) or 1 major and 2 minor (e.g., cough at night, dyspnea
on ordinary exertion) criteria.8 Patients who developed ADHF
during admission for another acute illness (e.g., acute
myocardial infarction) or following an interventional procedure
were excluded.
Data on patient demographics, medical history, clinical
characteristics, presenting symptoms, physical examination
ﬁndings, test results, medications, implantable devices, and
other therapies were collected. A statewide review of death
certiﬁcates, the Social Security Death Index, and review of
hospital medical records at participating medical centers for
subsequent hospitalizations or medical care contacts was
carried out to ascertain the posthospital discharge survival
status of study patients.
Data Analysis
We examined differences in the characteristics of patients in
each of our 4 study years using ANOVA and Mantel-Haenszel
chi square tests for continuous and discrete variables,
respectively. The Mantel-Haenszel chi square test was used
to examine the statistical signiﬁcance of trends in changing
patient characteristics during the years under study
(Table 1).
In-hospital and 30-day case-fatality rates (CFRs) were
calculated in a standard manner. We used a life-table
approach to examine all-cause mortality patterns in greater
Worcester residents discharged from all central Massachu-
setts medical centers after hospitalization for ADHF. Multi-
variable logistic regression analysis was used to examine
changes over time in in-hospital and 30-day CFRs while
controlling for several factors of prognostic importance. A Cox
proportional hazards regression approach was utilized to
identify demographic, medical history, laboratory, and clinical
factors associated with a poor prognosis after hospital
discharge for ADHF during the 5 year post discharge follow-
up period while controlling for potentially confounding factors
and duration of follow-up. Multivariable adjusted hazards
ratios (HR) and accompanying 95% conﬁdence intervals (CI)
for factors associated with a poor prognosis after hospital
discharge were calculated. In all calculated odds ratios and
hazards ratios in our regression models, 1995 served as the
referent year (Tables 2 and 4). Clustering within hospitals was
accounted for in all regression models by using the survey-
logistic procedure in SAS where hospital was speciﬁed as a
cluster to avoid the underestimation of standard deviations
and standard errors. Proportionality assumptions for the Cox
regression model were tested with the goodness-of-ﬁt test
and were met for all analyses. We utilized commonly used
cutpoints to categorize a number of the physiologic and
laboratory values examined, as opposed to expressing these
factors as continuous variables, to make the results more
clinically meaningful and interpretable.
Since we did not have information available about patients’
clinical or treatment status after hospital discharge, we
focused our analysis on factors associated with long-term
survival that could be identiﬁed during the index hospitaliza-
tion. In our multivariable adjusted regression analyses, we did
not control for the use of in-hospital therapies due to the
nonrandomized observational nature of this study and
potential for confounding by treatment indication. Further-
more, we did not include treatment variables in our regression
models due to the difﬁculty in interpretation of any ﬁndings.
Since ejection fraction (EF) data were assessed in only one-
third of study patients during their index hospitalization, we
did not stratify our results according to EF ﬁndings or by type
of HF (preserved or reduced EF).
Results
Baseline Characteristics
A total of 9748 metropolitan Worcester residents were
discharged from all central Massachusetts medical centers
with independently conﬁrmed ADHF in 1995, 2000, 2002, and
2004. The average age of this population was 76 years, 94%
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Table 1. Demographic and Clinical Characteristics of Patients Hospitalized With Acute Decompensated Heart Failure
Total Population
(n=9748)
1995 Cohort
(n=1949)
2000 Cohort
(n=2587)
2002 Cohort
(n=2743)
2004 Cohort
(n=2469)
P-Value for
Trend*
Age (mean, y) 76.2 (12.1) 75.7 (11.0) 76.3 (12.3) 76.4 (12.3) 76.2 (12.6) 0.19
Age (y), %
<65 15.6 14.3 15.3 16.0 16.7 <0.01
65 to 74 21.5 26.9 20.0 19.8 20.8
75 to 84 37.1 37.5 38.7 38.0 34.1
≥85 25.7 21.4 27.0 26.2 28.4
Male 43.9 42.9 43.3 42.7 46.9 <0.05
White 93.8 96.8 93.8 93.1 92.3 <0.001
Incident event 29.0 26.1 24.9 28.6 36.4 <0.001
Body mass index, kg/m2 27.7 (7.6) 26.8 (7.3) 27.6 (7.5) 28.3 (8.0) 28.1 (7.4) <0.001
Cholesterol, mg/dL 162.5 (46.0) 175.6 (49.0) 166.9 (48.1) 159.8 (42.6) 150.4 (41.4) <0.001
Systolic blood pressure,
mm Hg
142.7 (32.1) 145.9 (32.5) 143.2 (31.6) 141.8 (32.1) 140.5 (32.1) <0.001
Diastolic blood pressure,
mm Hg
74.7 (19.1) 79.1 (18.4) 75.1 (19.0) 73.2 (19.3) 72.5 (19.1) <0.001
Creatinine, mg/dL 1.64 (1.26) 1.57 (1.13) 1.63 (1.21) 1.59 (1.13) 1.77 (1.51) <0.001
Estimated GFR, mL/min
per 1.73 m2
50.9 (23.7) 51.8 (23.2) 50.9 (23.5) 51.5 (23.9) 49.4 (23.9) <0.01
Blood urea nitrogen, mg/dL 34.4 (25.8) 33.3 (23.7) 35.2 (25.4) 33.5 (23.5) 35.5 (30.2) <0.005
Serum sodium, mmol/L 137.4 (5.5) 137.7 (5.1) 136.9 (5.7) 137.0 (5.7) 138.1 (5.5) <0.001
Glucose, mg/dL 158.5 (69.3) 165.6 (75.9) 161.5 (69.8) 155.9 (66.2) 152.5 (66.1) <0.001
Ejection fraction (EF), % 45.4 (16.6) 41.7 (14.9) 44.4 (16.0) 46.6 (17.0) 46.9 (17.0) <0.001
EF ≥50% 49.5 34.6 47.8 53.3 53.9 <0.001
EF <40%† 36.8 45.5 38.0 34.4 34.4 <0.001
LOS, days 6.1 (7.8) 7.4 (8.1) 5.5 (6.6) 6.0 (7.6) 6.1 (8.7) <0.001
Medical history, %
Anemia 24.6 21.9 24.6 24.6 26.7 <0.001
Coronary heart disease 56.0 57.0 56.7 54.8 55.7 0.23
Chronic lung disease 35.9 35.5 34.3 37.9 35.7 0.37
Diabetes 39.0 39.7 39.9 37.5 39.3 0.39
Hypertension 68.7 62.3 67.3 70.7 72.8 <0.001
Peripheral vascular disease 19.7 20.2 16.7 20.9 21.0 0.22
Renal failure/Disease 25.9 21.5 24.6 25.5 31.4 <0.001
Stroke 13.2 14.3 14.8 12.9 11.5 <0.01
Symptoms, %
Angina/Chest pain 31.2 31.2 30.1 33.4 29.9 0.96
Dyspnea/Shortness of breath 93.4 96.5 93.1 92.6 92.2 <0.001
Swelling 70.3 63.8 70.3 72.7 72.7 <0.001
Nausea/Vomiting 16 14.2 14.9 17.4 17.1 <0.01
Orthopnea 35.4 29.2 36.7 36.1 38.4 <0.001
Weakness 25.1 24.9 28.5 23.1 23.8 0.11
Weight gain 8.0 6.8 8.9 7.3 8.9 <0.05
Continued
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were white, 56% were women, and 29% were hospitalized with
HF for the ﬁrst time (incident cases) (Table 1). Overall,
patients with ADHF had a high burden of comorbid cardio-
vascular and noncardiovascular diseases including hyperten-
sion (69%), coronary artery disease (56%), diabetes (39%),
chronic obstructive pulmonary disease (36%), and chronic
kidney disease (26%).
Compared with patients presenting to greater Worcester
hospitals in 1995, patients hospitalized with ADHF during
more recent study years were older, more likely to be male,
non-white, and to present with an incident (initial episode) HF
event (Table 1). These patients were also more likely to be
heavier and to have lower serum cholesterol, blood pressure,
estimated glomerular ﬁltration rate ﬁndings, and serum
glucose levels, but higher serum levels of blood urea nitrogen
and sodium. Patients hospitalized in the most recent study
years had, on average, a shorter hospital stay, and, in the
more limited sample of patients with data available on EF
ﬁndings, there was a trend toward increasing average EF
results during the years under study. Patients hospitalized in
more recent study years were also more likely to have a
history of anemia, hypertension, chronic kidney disease, and
stroke. Patients presenting with an initial episode of ADHF
had fewer comorbidities and symptomatic complaints com-
pared with the total study population.
In examining changing trends in hospital treatment prac-
tices during the years under study, patients hospitalized
during recent study years were more likely to have been
treated with aspirin, beta blockers, and lipid lowering agents;
on the other hand, patients were less likely to have been
treated with calcium channel blockers and digoxin during
more recent as compared with earlier study years (Table 1).
Relatively similar trends were observed with regards to the
prescribing of these medications at the time of hospital
discharge (data not shown).
In-Hospital and 30-Day Case-Fatality Rates
In-hospital and 30-day case fatality rates for all hospitalized
patients, and separately for incident (initial) cases of ADHF,
are shown in Table 2. During the period under study, a total of
704 (7.2%) patients died during their index hospitalization
while 752 (8.3%) patients died within 30 days after hospital
discharge. In 1995, 8.5% of patients admitted for ADHF died
during hospitalization with inconsistent declines in hospital
death rates noted between 2000, 2002, and 2004 (Table 2). In
1995, 8.5% of patients died within 30 days following hospital
discharge for ADHF compared with 7.1% in 2004. Similar,
albeit inconsistent, declining trends in in-hospital and 30-day
all-cause mortality rates were also observed in patients with an
initial episode of ADHF.
After controlling for age, sex, and all major baseline
comorbidities and physiologic variables (listed in Table 1), the
multivariable adjusted odds of dying during hospitalization,
and within 30-days after hospital discharge, declined over
time in both the total study population and in incident cases
of ADHF (Table 2). Similar, however, to what had been
observed in our crude unadjusted analyses, there was an
inconsistent decline in in-hospital death rates observed during
the years under study after multivariable adjustment.
Postdischarge Survival Rates
The median follow-up time for the study was 1.6 years. Of the
9748 patients hospitalized with ADHF in this study, 8556
(87.8%) died within the ﬁrst 5 years postdischarge. At all
postdischarge time points examined, the survival rate of
patients hospitalized with ADHF improved appreciably
between 1995 and 2004, despite the presence of an
increasingly older and more comorbid patient population
(Figure and Table 3). Five-year postdischarge survival rates in
Table 1. Continued
Total Population
(n=9748)
1995 Cohort
(n=1949)
2000 Cohort
(n=2587)
2002 Cohort
(n=2743)
2004 Cohort
(n=2469)
P-Value for
Trend*
Medication
ACE inhibitors/ARB’s 51.5 50.4 52.0 51.9 51.4 0.46
Aspirin 56.3 41.1 57.3 60.0 63.1 <0.001
Beta blockers 55.3 26.2 51.8 62.5 73.7 <0.001
Calcium channel blockers 32.7 40.2 33.9 29.8 29.7 <0.001
Lipid lowering agents 27.3 5.8 21.0 32.8 44.9 <0.001
Diuretics 97.1 97.9 97.7 96.6 96.4 <0.01
Digoxin 43.5 55.0 47.2 41.2 33.3 <0.001
Data are given as percentages or meanSD unless otherwise noted. GFR indicates glomerular ﬁltration rate; LOS, length of stay; ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor blocker.
*Mantel-Haenszel chi square test for trend.
†Missing in 63% of cases.
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1995, 2000, 2002, and 2004 were 20%, 22%, 27%, and 29%,
respectively.
Further analysis showed that survival rates improved
markedly for patients who survived the ﬁrst year posthospi-
talization for ADHF. In 2004, survival rates were 79% at
2 years postdischarge for patients that had already survived
1 year with ADHF, as compared to 52% at 2 years postdis-
charge for patients in the total population. A similar pattern
was noted among patients with an incident episode of ADHF.
Multivariable regression models controlling for a number of
different patient demographic, clustering by hospital, clinical,
physiologic, and laboratory characteristics of prognostic
importance (Table 1) demonstrated signiﬁcantly reduced
hazards rates for the risk of dying in all subsequent study
years compared with 1995 (Table 4). For example, the
multivariable adjusted HR for dying in 2004 was 0.63 (95%
CI 0.53 to 0.74) while the HR for incident cases of HF in 2004
was 0.60 (95% CI 0.48 to 0.74) compared with patients
hospitalized in the initial study year of 1995.
Factors Associated With Decreased Survival After
Hospital Discharge
A Cox proportional hazards regression analysis was con-
ducted to identify patient characteristics independently
associated with increased postdischarge mortality for both
incident cases and all cases of ADHF (Table 5). This analysis
showed that older age, male sex, prior HF, anemia, chronic
obstructive pulmonary disease, diabetes, peripheral vascular
disease, chronic kidney disease, stroke, and low blood
pressures at the time of hospital presentation were associ-
ated with poorer long-term survival. Higher serum levels of
blood urea nitrogen and lower levels of serum sodium were
associated with poorer long-term survival. These factors were
adversely associated with long-term prognosis for all cases of
ADHF and for incident cases with this clinical syndrome.Ta
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Figure. Long-term survival after hospital discharge for acute
decompensated heart failure.
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Discussion
The principal ﬁnding of this community-wide study of patients
hospitalized with ADHF between 1995 and 2004 was a
marked improvement in long-term post hospital discharge
survival (5-year survival improved from 20% to 29%) during the
decade-long period under study. There were also improve-
ments in both in-hospital and 30-day postdischarge survival,
though these trends were somewhat inconsistent during the
years under study. These improvements in survival are
particularly notable given that patients admitted with ADHF
have become increasingly elderly and debilitated over time.
Although survival improved substantially during the years
under study, the overall prognosis of patients hospitalized
with ADHF remained poor, with fewer than 1 in 3 patients
hospitalized in 2004 surviving more than 5 years. Older age, a
history of previously diagnosed HF, low blood pressures, and a
variety of comorbidities were independently associated with
decreased long-term survival.
Study Population Characteristics
The baseline characteristics of patients hospitalized with
ADHF in this study were comparable to those of patients
enrolled in large HF registries in the United States and Europe,
such as the Acute Decompensated Heart Failure National
Registry, 2002–2004 (ADHERE), Organized Program to Initiate
Lifesaving Treatment in Patients Hospitalized with Heart
Failure, 2003-2004( OPTIMIZE-HF), and Euro Heart Failure
Survey I, 2001–2002 and II, 2005 (EHFS).9–14 These studies
have shown that patients hospitalized with ADHF are typically
in their mid-70s, a slight majority are women, and multiple
cardiovascular and noncardiovascular comorbidities, including
prior HF, are present.
Notably, patients admitted with ADHF in our study were
signiﬁcantly older and were more medically complex over
time. Although the average age of our study population
increased by only 0.5 years between 1995 and 2004, the
proportion of patients 85 years and older increased by one-
third over time, from 21% in 1995 to 28% in 2004. Patients
admitted with ADHF in 2004 were signiﬁcantly more likely to
have a history of chronic renal disease, hypertension, and
anemia, as well as a higher body mass index, compared with
those admitted in 1995. Additionally, patients admitted to
central Massachusetts medical centers in 2004 were more
likely to have lower serum cholesterol and glucose levels and
lower blood pressures, likely due to the more extensive use of
statins, antihypertensives, and antihyperglycemic medica-
tions, than patients admitted during earlier study years.5–7
Of interest, there was an increasing proportion of patients
hospitalized with an initial episode of ADHF over time. While
the reasons for this somewhat unexpected increase are
unknown, this changing trend may be due to an increasing
pool of patients with cardiovascular disease at risk for ADHF,
changing natural history of this clinical syndrome, or to
changing diagnostic or hospital admission practices during
the years under study.
Trends in In-Hospital and 30-Day Case-Fatality
Rates
Few studies, especially from the more generalizable perspec-
tive of a population-based investigation, have examined
Table 4. Changes Over Time in the Crude and Multivariable Adjusted Odds of Dying After Hospital Discharge for Patients With
Decompensated Acute Heart Failure
Study Year Unadjusted Hazard Ratio Age and Sex Adjusted Hazard Ratio Multivariable Adjusted Hazard Ratio*
1995† 1.0 1.0 1.0
2000 0.86 (0.74 to 1.00)‡ 0.85 (0.75 to 0.97) 0.82 (0.75 to 0.90)
2002 0.76 (0.68 to 0.86) 0.75 (0.69 to 0.82) 0.73 (0.69 to 0.78)
2004 0.68 (0.52 to 0.88) 0.67 (0.54 to 0.83) 0.63 (0.53 to 0.74)
*Adjusted for age, sex, race, clustering by hospital, history of anemia, coronary artery disease, chronic obstructive pulmonary disease, diabetes, hypertension, peripheral vascular disease,
renal disease or stroke, estimated glomerular ﬁltration rate, serum glucose, sodium, and blood urea nitrogen levels, systolic and diastolic blood pressure, heart rate, and length of hospital
stay.
†Referent year.
‡95% CI.
Table 3. Post Hospital Discharge Case-Fatality Rates At
Selected Time Points in Patients With Acute Decompensated
Heart Failure According to Study Year
Study Year 1 Year (%) 2 Years (%) 5 Years (%)
1995 41.4 57.4 80.3
2000 38.4 54.5 77.9
2002 35.9 46.6 72.9
2004 34.7 45.3 70.5
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trends in in-hospital and short-term CFR’s among patients
hospitalized with ADHF. In a prior cross-sectional study, the
OPTIMIZE-HF study group reported a 3.8% in-hospital death
rate among 48 612 patients hospitalized with ADHF in 259
centers between 2003 and 2004,10 while a 6.7% in-hospital
CFR was observed in the EHFS, a study of 3580 patients
hospitalized in 133 centers in 30 countries in the early
2000’s.12,15 The in-hospital death rate in EHFS was similar to
the mortality rate observed in the present study. The lower in-
hospital mortality rate found in OPTIMIZE-HF was likely
related to the lower age and overall disease acuity of this
patient population, as well as to a variety of other possible
contributory factors.
No prior population-based studies have assessed trends in
hospital and short-term postdischarge death rates in patients
with ADHF. Our study supports previous ﬁndings from a
national registry of 159 168 patients hospitalized with HF
between 2002 and 2004 (ADHERE),9 in which multivariable-
adjusted in-hospital CFRs declined from 4.5% to 3.1%. While
somewhat higher in-hospital CFRs were found in our popu-
lation-based study, we also observed relative declines in
short-term death rates of approximately 20% during the years
under study. Our study population was on average 4 years
older than patients in ADHERE, though patients in both
studies had a similar proﬁle of comorbidities.
Although differences in the duration of hospitalization or
patient demographic and clinical characteristics over time
could have affected trends in hospital mortality, there
remained a clinically meaningful decline in the multivariable
adjusted odds of dying in the hospital and at 30 days after
hospital discharge between 1995 and 2004 after controlling
for a number of potentially confounding factors including
comorbidities, physiologic variables, and hospital length of
stay. It is likely that the greater use of effective cardiac
therapies, and implementation of advances in interventional
Table 5. Factors Associated With Postdischarge Mortality
Factor
All Patients Incident Cases
HR 95% CI HR 95% CI
Age, y
<65 1.00 — 1.00 —
65 to 74 1.43 1.21 to 1.70 1.62 1.52 to 1.73
75 to 84 1.89 1.64 to 2.18 2.22 1.96 to 2.51
≥85 2.62 2.29 to 2.99 3.16 2.75 to 3.63
Male 1.06 1.02 to 1.10 1.24 1.04 to 1.47
White race 1.39 1.22 to 1.59 1.61 1.38 to 1.86
Incident case 0.74 0.65 to 0.83 — —
Medical history
Anemia 1.13 1.06 to 1.20 1.23 1.04 to 1.44
Coronary
heart disease
1.00 0.95 to 1.06 0.99 0.93 to 1.06
Chronic
obstructive
pulmonary
disease
1.26 1.19 to 1.34 1.48 1.35 to 1.63
Diabetes 1.08 1.01 to 1.15 1.08 0.98 to 1.18
Hypertension 0.88 0.84 to 0.92 0.89 0.77 to 1.01
Peripheral
vascular
disease
1.09 1.01 to 1.18 1.14 1.07 to 1.20
Renal disease 1.11 1.04 to 1.20 1.11 0.98 to 1.26
Stroke 1.19 1.14 to 1.24 1.22 1.08 to 1.38
Estimated GFR, mL/min per 1.73 m2
<30 1.21 1.04 to 1.42 1.30 0.89 to 1.89
30 to 59 1.08 1.01 to 1.14 1.10 1.03 to 1.18
≥60 1.0 — 1.0 —
Serum glucose, mg/dL
<140 1.00 — 1.00 —
140 to 199 1.00 0.95 to 1.05 0.99 0.90 to 1.09
≥200 1.02 0.91 to 1.14 1.14 0.92 to 1.41
Systolic BP, mm Hg
<100 1.0 — 1.0 —
100 to 159 0.78 0.73 to 0.84 0.89 0.76 to 1.04
≥160 0.66 0.60 to 0.72 0.75 0.61 to 0.92
Diastolic BP, mm Hg
<60 1.0 — 1.0 —
60 to 89 0.99 0.94 to 1.04 0.93 0.89 to 0.98
≥90 0.96 0.90 to 1.02 0.97 0.90 to 1.04
Heart rate, bpm
<60 1.0 — 1.0 —
60 to 99 1.05 0.91 to 1.21 1.14 0.93 to 1.40
≥100 1.16 1.05 to 1.28 1.16 0.96 to 1.42
Continued
Table 5. Continued
Factor
All Patients Incident Cases
HR 95% CI HR 95% CI
Blood urea nitrogen, mg/dL
<43 1.0 — 1.0 —
≥43 1.45 1.30 to 1.62 1.32 0.94 to 1.86
Serum sodium, mmol/L
<135 1.15 1.13 to 1.18 1.10 1.06 to 1.15
≥135 1.0 — 1.0 —
Referent groups: age <65 years, female sex, absence of listed comorbidities, eGFR
≥60 mL/min per 1.73 m2, serum glucose <140 mg/dL, systolic blood pressure
<100 mm Hg, diastolic blood pressure <60 mm Hg, heart rate <60 bpm, blood urea
nitrogen <43 mg/dL, and serum sodium ≥135 mmol/L. GFR indicates glomerular
ﬁltration rate; BP, blood pressure.
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procedures, have contributed to these encouraging trends.
Improved patient education, discharge processes, and post-
discharge care may have also contributed to reduced
postdischarge mortality.
Trends in Long-Term Prognosis
Although the 5-year mortality rates following hospital dis-
charge for ADHF remained high in the present investigation,
we and other research groups have shown signiﬁcant
improvements in long-term survival among patients dis-
charged from the hospital after ADHF. Our ﬁndings of
improved multivariable-adjusted postdischarge survival rates
in both the total study population and in those with a ﬁrst
episode of ADHF are consistent with earlier observational
studies in the United States2,3 and Scotland.16 The popula-
tion-based Framingham Study demonstrated a 12% decline in
mortality risk per decade (1950-1999) in study participants
after the diagnosis of HF.2 In a cohort study from Olmsted
County, MN, a decline in 5 year age-adjusted death rates from
57% to 48% was observed among patients with a ﬁrst
diagnosis of HF between 1979 and 2000.3 In the large
national Scottish cohort study of all patients admitted with a
principal diagnosis of HF between 1986 and 1995, long-term
CFRs declined by 18% in men and 15% in women over the
decade-long period under study.16 In a prior study of the
metropolitan Worcester population, we examined the long-
term prognosis of patients discharged from all greater
Worcester medical centers after being hospitalized for ADHF
in 1995 and 2000, ﬁnding improving trends in long-term
prognosis.6 The present study extends these prior ﬁndings by
examining more recent study years, particularly during a time
of changing HF guidelines, management practices, risk factor
modiﬁcation, and quality improvement initiatives.4,13,17–22
Study Strengths and Limitations
The primary strengths of this study were the large, population-
based sample with independently validated hospitalization for
ADHF, detailed information on patient demographic and
clinical characteristics, and the comprehensive follow-up of
discharged study patients. Limitations of this study included a
predominantly white population from a single region in central
New England, lack of information on postdischarge events
other than death, and the inability to evaluate prognosis
according to type of HF (reduced versus preserved systolic
function) due to limited availability of EF data for study
patients. Information on cause-speciﬁc mortality was not
collected. Finally, we were unable to evaluate the potentially
beneﬁcial effects of the therapies examined in this study
given the nonrandomized nature of this investigation and the
potential for confounding by drug indication. We also did not
collect data on the use of medications by patients on a long-
term basis after hospital discharge for ADHF.
Conclusions
Admissions for ADHF were increasingly dominated by elderly
patients with multiple comorbidities, who often required a
prolonged hospital stay. Although both short- and long-term
survival for these patients improved signiﬁcantly between
1995 and 2004, their long-term prognosis remains poor, as
fewer than 1 in 3 patients hospitalized with ADHF in 2004
survived more than 5 years. While there has been encourag-
ing progress in the treatment and prognosis of patients
hospitalized with ADHF, additional opportunity remains to
improve the in-hospital and postdischarge management of
patients with this common and debilitating clinical syndrome.
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